Cargando…

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases

Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory drugs for treating chronic inflammatory diseases. Modulation of systemic and airway inflammation is their pivotal mechanism of action. Furthermore, PDE inhibitors modulate cough reflex and inhibit airway mucus s...

Descripción completa

Detalles Bibliográficos
Autor principal:	Kawamatawong, Theerasuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381854/ https://www.ncbi.nlm.nih.gov/pubmed/34434103 http://dx.doi.org/10.3389/fphar.2021.518345

Ejemplares similares

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients
por: Kawamatawong, Theerasuk, et al.
Publicado: (2018)

Serum inflammatory biomarkers and clinical outcomes of COPD exacerbation caused by different pathogens
por: Kawamatawong, Theerasuk, et al.
Publicado: (2017)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
por: Joskova, Marta, et al.
Publicado: (2020)

Assessment of proximal and peripheral airway dysfunction by computed tomography and respiratory impedance in asthma and COPD patients with fixed airflow obstruction
por: Pornsuriyasak, Prapaporn, et al.
Publicado: (2018)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment
por: Tharanon, Vichapat, et al.
Publicado: (2022)

The asthma and chronic obstructive pulmonary disease overlap syndrome in tertiary care setting Thailand
por: Kawamatawong, Theerasuk, et al.
Publicado: (2017)

Erratum: Correction of Figure 1: The asthma and chronic obstructive pulmonary disease overlap syndrome in tertiary care setting Thailand
por: Kawamatawong, Theerasuk, et al.
Publicado: (2018)

Peak inspiratory flow rate measurement by using In-Check DIAL for the different inhaler devices in elderly with obstructive airway diseases
por: Kawamatawong, Theerasuk, et al.
Publicado: (2017)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Role of eosinophilic inflammation and atopy in elderly asthmatic patients
por: Kawamatawong, Theerasuk, et al.
Publicado: (2016)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review
por: Ahmad, Nazir, et al.
Publicado: (2022)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Substrate-Dependence of Competitive Nucleotide Pyrophosphatase/Phosphodiesterase1 (NPP1) Inhibitors
por: Lee, Sang-Yong, et al.
Publicado: (2017)

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
por: Bondarev, Andrey D., et al.
Publicado: (2022)

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis
por: Totani, Licia, et al.
Publicado: (2021)

Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases
por: Mokry, Juraj, et al.
Publicado: (2021)

In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania amazonensis
por: Silva, Dahara Keyse Carvalho, et al.
Publicado: (2020)

East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease
por: Sharma, Manju, et al.
Publicado: (2018)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Effects of Oral Procaterol for Postinfectious Cough in Adults: Single-Centre, Randomized Double-Blind, Placebo-Controlled Trial
por: Pornsuriyasak, Prapaporn, et al.
Publicado: (2021)

Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
por: Martin, Clémence, et al.
Publicado: (2021)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells
por: Grundy, Seamus, et al.
Publicado: (2016)

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
por: Singh, Dave, et al.
Publicado: (2018)

A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
por: Singh, Dave, et al.
Publicado: (2020)

Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice
por: Blednov, Yuri A., et al.
Publicado: (2014)

Editorial: Cyclic Nucleotide Phosphodiesterases (PDEs) in Immune Regulation and Inflammation
por: Brocke, Stefan, et al.
Publicado: (2022)

Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion
por: Kim, Hee Kee, et al.
Publicado: (2017)

Reversal of spatial memory impairment by phosphodiesterase 3 inhibitor cilostazol is associated with reduced neuroinflammation and increased cerebral glucose uptake in aged male mice
por: Yanai, Shuichi, et al.
Publicado: (2022)

Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases
por: Nguyen, Hoang Oanh, et al.
Publicado: (2023)

Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?
por: Goonathilake, Mastiyage R, et al.
Publicado: (2022)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
por: Yu, Haichuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h4gdj0gp8s5u5eo44989k0n5qv